Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Dec 20;36(3):129–134. [Article in Spanish] doi: 10.1157/13077478

Seguimiento farmacoterapéutico de pacientes en farmacias comunitarias

Pharmacotherapeutic follow-up of patients in community pharmacies

P Armando a,⁎, N Semería b, M Tenllado b, N Sola a
PMCID: PMC7676049  PMID: 16029741

Abstract

Objective

To analyse pharmacist intervention (PI) resulting from the implementation of the Dáder Pharmacotherapeutic Follow-Up Program (PFU).

Design

Descriptive study of the findings from the PFU program during the first year.

Setting

Community pharmacists in area of the College of Pharmacists of the Province of Cordoba (Argentina).

Participants

A total of 202 patients were included in the PFU, selected on the basis of the observed needs by each of the participating pharmacists.

Principal measurements

From the resulting PI reports the sex and age were obtained and problems related to medication (PRM) were classified according to the Second Consensus of Granada. The method of resolving PRM, the number of medications used and the number of visits made to the pharmacy to resolve each of them.

Results

38 pharmacists participated and 108 patients were registered in the PI. The number of PI increased to 280, with 218 PRM resolved (77.9% effectiveness: 95% confidence interval [CI], 70.6-86.2). 25% of the PRM were resoled between the pharmacist and the patient and 75% required the participation of the doctor, the PI achieving an acceptance of 74.6% (95% CI, 67.8-82.6).

Conclusions

A high percentage of resolving PRM was obtained, with a significant acceptance of the PI by the doctors, which demonstrates the feasibility of including community pharmacists in the medical team and the possibility that they could make a significant contribution in decreasing the morbility and mortality associated with medications by carrying out PFU activities.

Key words: Pharmacotherapeutic follow-up, Problems related to medications, Pharmaceutical care, Dáder Program, Pharmacist interventions

Bibliografía

  • 1.Garratini S. «Pharmacocentricity»: from elixirs to magic bullets. Lancet. 1999;354(Suppl 4):51. doi: 10.1016/s0140-6736(99)90394-x. [DOI] [PubMed] [Google Scholar]
  • 2.Hepler C.D., Strand L.M. Opportunities and responsabilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543. [PubMed] [Google Scholar]
  • 3.Strand L., Morley P.C., Cipolle R.J., Ramsey R., Lamsam G.D. Drug-related problems: theirs structure and function. Ann Pharmacother. 1990;24:1093–1097. doi: 10.1177/106002809002401114. [DOI] [PubMed] [Google Scholar]
  • 4.Faus Dáder M.J., Martínez Romero F. La atención farmacéutica en farmacia comunitaria: evolución de conceptos, necesidades de formación, modalidades y estrategias para su puesta en marcha. Pharm Care Esp. 1999;1:52–61. [Google Scholar]
  • 5.Segundo Consenso de Granada sobre Problemas Relacionados con Medicamentos Grupo de Investigación en Atención Farmacéutica (CTS-131). Universidad de Granada. Grupo de Investigación en Farmacología Aplicada y Farmacoterapia (CTS- 259). Universidad de Sevilla. Grupo de Investigación en Farmacología de Productos Naturales (CTS-164). Universidad de Granada. Ars Pharmaceutica. 2002;43:175–184. [Google Scholar]
  • 6.Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200–1205. doi: 10.1001/jama.279.15.1200. [DOI] [PubMed] [Google Scholar]
  • 7.Bates D.W., Cullen D.J., Laird N., Petersen L.A., Small S.D., Servi D. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA. 1995;274:29–34. [PubMed] [Google Scholar]
  • 8.Mohammad J.T., Melby M.J., Kaback K.R., Nord T.C. Medicationrelated visits to the emergency department: a prospective study. Annals Pharmacother. 1999;33:1252–1257. doi: 10.1345/aph.19062. [DOI] [PubMed] [Google Scholar]
  • 9.Tuneu L., Valls L., García-Peláez M., López Sánchez S., Serra Soler G., Alba Aranda G., De Irala Indart C. Problemas relacionados con los medicamentos en pacientes que ingresan en un servicio de urgencias. Pharm Care Esp. 2000;3:177–192. [Google Scholar]
  • 10.Johnson J.A., Bootman J.L, Drug-related morbidity and mortality A cost-of-illness model. Arch Intern Med. 1995;155:1949–1956. [PubMed] [Google Scholar]
  • 11.Ernst F., Grizzle A. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192–199. doi: 10.1016/s1086-5802(16)31229-3. [DOI] [PubMed] [Google Scholar]
  • 12.Hepler C.D. Regulating for outcomes as a systems response to the problem of drug-related morbidity. J Am Pharm Assoc. 2001;41:108–115. doi: 10.1016/s1086-5802(16)31211-6. [DOI] [PubMed] [Google Scholar]
  • 13.Uema S., Armando P., Solá N. Propuesta de cambio para la dispensación de medicamentos en la farmacia comunitaria. Medicamentos y Salud. 2003;4:28–33. [Google Scholar]
  • 14.El papel del farmacéutico en el sistema de atención de salud. Informe de la Reunión de la OMS. Tokio, Japón, 1993. Primera parte. Segunda reunión de la OMS sobre la función de farmacéutico. Servicios farmacéuticos de calidad: ventajas para los gobiernos y el público. Segunda parte. Federación Internacional Farmacéutica (FIP). La Declaración de Tokio. Buenas Prácticas de Farmacia: Normas de Calidad de Servicios Farmacéuticos.
  • 15.Ministerio de Sanidad y Consumo . Secretaría General Técnica Centro de Publicaciones; Madrid: 2001. Dirección General de Farmacia y Productos Sanitarios. Consenso de Atención Farmacéutica. [Google Scholar]
  • 16.Martínez-Romero F., Fernández-Llimós F., Gastelurrutia M.A., Parras M., Faus M.J. Programa Dáder de Seguimiento del Tratamiento Farmacológico. Resultados de la Fase Piloto. Ars Pharmaceutica. 2001;42:53–65. [Google Scholar]
  • 17.Fernández-Llimós F., Faus M.J. Resultados del Programa Dáder de Seguimiento Farmacoterapéutico del Paciente en España. El Farmacéutico. 2002;290:83–89. [Google Scholar]
  • 18.Ellis S.L., Carter B.L., Malone D.C., Billups S.J., Okano G.J., Valuck R.J. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000;20:1508–1516. doi: 10.1592/phco.20.19.1508.34852. [DOI] [PubMed] [Google Scholar]
  • 19.Malone D.C., Carter B.L., Billups S.J., Valuck R.J., Barnette D.J., Sintek C.D. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for highrisk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000;20:1149–1158. doi: 10.1592/phco.20.15.1149.34590. [DOI] [PubMed] [Google Scholar]
  • 20.Grainger-Rousseau T.J., Miralles M.A., Hepler C.D., Segal R., Doty R.E., Ben-Joseph R. Therapeutic outcomes monitoring: application of pharmaceutical care guidelines to community pharmacy. J Am Pharm Assoc. 1997;NS37:647–661. doi: 10.1016/s1086-5802(16)30281-9. [DOI] [PubMed] [Google Scholar]
  • 21.Nola K.M., Gourley D.R., Portner T.S., Gourley G.K., Solomon D.K., Elam M. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc. 2000;40:166–173. doi: 10.1016/s1086-5802(16)31060-9. [DOI] [PubMed] [Google Scholar]
  • 22.Solomon D.K., Portner T.S., Bass G.E., Gourley D.R., Gourley G.A., Holt J.M. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc. 1998;38:574–585. doi: 10.1016/s1086-5802(16)30371-0. [DOI] [PubMed] [Google Scholar]
  • 23.Volume C.I., Farris K.B., Kassam R., Cox C.E., Cave A. Pharmaceutical care research and education project: patient outcomes. J Am Pharm Assoc. 2001;41:411–420. doi: 10.1016/s1086-5802(16)31255-4. [DOI] [PubMed] [Google Scholar]
  • 24.Kassam R., Farris K.B., Burback L., Volume C.I., Cox C.E., Cave A. Pharmaceutical care research and education project: pharmacists’ interventions. J Am Pharm Assoc. 2001;41:401–410. doi: 10.1016/s1086-5802(16)31254-2. [DOI] [PubMed] [Google Scholar]
  • 25.Machuca M., Fernández-Llimós F., Faus M.J. Método Dáder. Guía de Seguimiento Farmacoterapéutico. Grupo de Investigación de Atención Farmacéutica (CTS-131). Universidad de Granada. Granada: La Gráfica, SC. 2003 [Google Scholar]
  • 26.Armando P., Semería N., Tenllado M.I., Solá N. Programa Dáder en Argentina: resultados del primer trimestre de actividades. Pharm Care España. 2001;3:196–203. [Google Scholar]
  • 27.Anatomical Therapeutic Chemical (ATC) Classification Index with defined daily doses (DDDs). WHO Collaborating Centre for Drug Statistics Methodology Oslo. 2000 [Google Scholar]
  • 28.Plaza Piñol F. La atención farmacéutica. Situación actual y evolución de la prestación farmacéutica: motivos del cambio. Pharm Care España. 1999;1:48–51. [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES